3-48575512-C-T
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000094.4(COL7A1):c.6007G>A(p.Gly2003Arg) variant causes a missense change. The variant allele was found at a frequency of 0.00000205 in 1,460,452 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G2003E) has been classified as Pathogenic.
Frequency
Consequence
NM_000094.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
COL7A1 | NM_000094.4 | c.6007G>A | p.Gly2003Arg | missense_variant | 74/119 | ENST00000681320.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
COL7A1 | ENST00000681320.1 | c.6007G>A | p.Gly2003Arg | missense_variant | 74/119 | NM_000094.4 | P1 | ||
COL7A1 | ENST00000328333.12 | c.6007G>A | p.Gly2003Arg | missense_variant | 73/118 | 1 | P1 | ||
COL7A1 | ENST00000487017.5 | n.1924G>A | non_coding_transcript_exon_variant | 39/83 | 5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1460452Hom.: 0 Cov.: 39 AF XY: 0.00000138 AC XY: 1AN XY: 726556
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | May 25, 2022 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the triple helix domain of COL7A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL7A1 are more frequently observed in individuals with disease than in the general population (PMID: 22058051). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL7A1 protein function. ClinVar contains an entry for this variant (Variation ID: 17430). This missense change has been observed in individuals with autosomal dominant dystrophic epidermolysis bullosa (PMID: 8752681, 29963685). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 2003 of the COL7A1 protein (p.Gly2003Arg). - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 06, 2022 | Located in the highly conserved Gly-X-Y repeat of the collagenous domain; Glycine substitution variants in this region of the COLVII protein destabilize the collagen triple helix resulting in skin fragility due to poor anchoring of the basement membrane to the underlying dermis (Pfendner and Lucky, 2018); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29722429, 21448560, 26707537, 8752681, 29963685, 20598510, 19681861, 8618021, 30523708, 34338359) - |
Epidermolysis bullosa dystrophica Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Dominant dystrophic epidermolysis bullosa with absence of skin Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 1996 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 01, 2015 | - - |
COL7A1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 15, 2023 | The COL7A1 c.6007G>A variant is predicted to result in the amino acid substitution p.Gly2003Arg. This variant has been reported in several individuals with autosomal dominant or autosomal recessive epidermolysis bullosa dystrophica (see for example, Christiano et al. 1996. PubMed ID: 8752681; Yenamandra et al. 2018. PubMed ID: 29963685; Sawka and Funk. 2021. PubMed ID: 34338359). This variant has not been reported in a large population database, indicating this variant is rare. The amino acid p.Gly2003Arg resides in exon 73 and is within the triple helical domain of the COL7A1 protein (amino acids 1254-2783); and, glycine substitution variants in the triple helical domain (Gly-X-Y; especially in exons 73, 74, and 75) are predominant in autosomal dominant dystrophic epidermolysis bullosa (DDEB; Pfendner and Lucky. 2018. PubMed ID: 20301481). This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at